Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 286 of the 288 references it cites were found in a registry or an index, and 2 are not checked yet; 18 of the 131 sources its claims cite were checked for support.

Intestinal microbiota in functional bowel disorders: a Rome foundation report

Open access

Abstract

It is increasingly perceived that gut host–microbial interactions are important elements in the pathogenesis of functional gastrointestinal disorders (FGID). The most convincing evidence to date is the finding that functional dyspepsia and irritable bowel syndrome (IBS) may develop in predisposed individuals following a bout of infectious gastroenteritis. There has been a great deal of interest in the potential clinical and therapeutic implications of small intestinal bacterial overgrowth in IBS. However, this theory has generated much debate because the evidence is largely based on breath tests which have not been validated. The introduction of culture-independent molecular techniques provides a major advancement in our understanding of the microbial community in FGID. Results from 16S rRNA-based microbiota profiling approaches demonstrate both quantitative and qualitative changes of mucosal and faecal gut microbiota, particularly in IBS. Investigators are also starting to measure host–microbial interactions in IBS. The current working hypothesis is that abnormal microbiota activate mucosal innate immune responses which increase epithelial permeability, activate nociceptive sensory pathways and dysregulate the enteric nervous system. While we await important insights in this field, the microbiota is already a therapeutic target. Existing controlled trials of dietary manipulation, prebiotics, probiotics, synbiotics and non-absorbable antibiotics are promising, although most are limited by suboptimal design and small sample size. In this article, the authors provide a critical review of current hypotheses regarding the pathogenetic involvement of microbiota in FGID and evaluate the results of microbiota-directed interventions. The authors also provide clinical guidance on modulation of gut microbiota in IBS.

Verified 2026-10-05 · 2 references not checked yet

Overview

CoChat Summary

TL;DR

This Rome Foundation report critically reviews evidence that gut microbiota contribute to functional bowel disorders, especially IBS, through post-infectious onset, altered mucosal/faecal communities, and host–microbial immune interactions. It concludes that microbiota-directed therapies are promising but limited by unvalidated SIBO tests, inconsistent microbiota findings, and underpowered trials.

Key findings

  • Post-infectious IBS is the most convincing link: infective gastroenteritis incidence is 19/100 person years in the UK; 6%–17% of IBS patients report onset after infective gastroenteritis (18% in an internet survey, with around 40% beginning while travelling), and a meta-analysis found increased IBS risk 1 year after bacterial gastroenteritis (RR=6.5, CI 2.6–15.4), still apparent at 36 months (RR=3.9, CI 3.0–5.0).
  • The SIBO hypothesis in IBS remains controversial because breath tests are not validated; lactulose hydrogen breath testing predominantly measures oro-caecal transit rather than SIBO, and culture studies show relatively few duodenal/proximal jejunal bacteria with no obvious differences from controls, though lower cut-offs (>10³ cfu/ml) suggest more IBS patients may meet SIBO criteria.
  • Culture-independent 16S rRNA-based profiling shows both quantitative and qualitative changes in mucosal and faecal microbiota in IBS, but results are inconsistent and sometimes contradictory; reported changes include decreased bifidobacteria/lactobacilli and increased Proteobacteria/Firmicutes in some studies, and faecal samples may not reflect other GI tract sites.
  • Microbiota-directed treatments show promise: rifaximin 550 mg thrice daily for 2 weeks had a therapeutic advantage over placebo around 10%, with benefit for approximately 10 weeks and number-needed-to-treat 11; about three-quarters of probiotic trials were positive with generally modest therapeutic gain, and the strongest evidence is for *Bifidobacterium infantis* 35624 at 1×10⁸ cfu/day for at least 4 weeks; one double-blind prebiotic trial using trans-galactooligosaccharide reduced symptoms and stimulated bifidobacteria.

Methods

  • Design: critical review and synthesis of the Rome Foundation Committee Report, not a primary study; it reviews current hypotheses on microbiota in FGID and evaluates microbiota-directed interventions.
  • Data: literature on intestinal microbiota in functional bowel disorders, focusing predominantly on IBS, including culture-based, culture-independent molecular, breath-test, and treatment studies; tables summarize small bowel culture studies, colonic microbiome studies, and placebo-controlled probiotic trials.
  • Analysis: narrative synthesis with clinical guidance and recommendations for future research; no systematic search strategy or meta-analysis is stated.

Limitations

  • The paper states that the SIBO hypothesis remains debated because breath tests and small bowel culture techniques have not been validated, and confounding factors such as antibiotics, PPIs, and altered motility have not been taken into account in many studies.
  • The paper states that most probiotic and antibiotic trials are underpowered and suffer suboptimal design; available studies are descriptive rather than mechanistic, and heterogeneity of FBD plus inter-individual variability of microbiota profiles require larger sample sizes.
  • Evident from the text: as a narrative review, it does not report a systematic search, formal quality assessment, or meta-analysis; many cited studies are small, older, or limited by poor quality, and the clinical guidance is based on limited evidence.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2012-302167

Cites

286 of 288 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Gut microbiota and the intrinsic and extrinsic factors that can affect its distribution and composition. A number of host mechanisms participate in gut microbiota modulation, including gastric acid secretion, fluid, anticommensal sIgA and antimicrobial peptide production, and gastrointestinal (GI) motility. Drugs that block acid secretion and affect GI motility can indirectly alter the microbiota. Antibiotics, depending on spectrum and dosage, will directly affect microbiota composition. Dietary modifications, including probiotic and fibre supplements, will also affect microbiota composition. MMC, migrating motor complexes; H+ hydrogen ions; O2, partial oxygen tension; sIgA, secretory immunoglobulin A; PPI, proton pump inhibitor; NSAID, non-steroidal anti-inflammatory drug.
Figure 1 Gut microbiota and the intrinsic and extrinsic factors that can affect its distribution and composition. A number of host mechanisms participate in gut microbiota modulation, including gastric acid secretion, fluid, anticommensal sIgA and antimicrobial peptide production, and gastrointestinal (GI) motility. Drugs that block acid secretion and affect GI motility can indirectly alter the microbiota. Antibiotics, depending on spectrum and dosage, will directly affect microbiota composition. Dietary modifications, including probiotic and fibre supplements, will also affect microbiota composition. MMC, migrating motor complexes; H+ hydrogen ions; O2, partial oxygen tension; sIgA, secretory immunoglobulin A; PPI, proton pump inhibitor; NSAID, non-steroidal anti-inflammatory drug.CC BY-NC · PubMed Central
Figure 2 Gut microbiota composition in African children living in rural areas with a polysaccharide-rich diet when compared with Italian city children.35 (Reprinted with permission from Proc Natl Acad Sci USA).
Figure 2 Gut microbiota composition in African children living in rural areas with a polysaccharide-rich diet when compared with Italian city children.35 (Reprinted with permission from Proc Natl Acad Sci USA).CC BY-NC · PubMed Central
Figure 3 The lactulose hydrogen breath test (LHBT) predominantly measures small intestinal transit rather than small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS) patients. Upper schematic shows ingestion of test meal with subsequent serial measurement of both H2 gas, resulting from fermentation of the lactulose by intestinal bacteria, and Tc99 scanning in the caecum. This latter measurement detects when the test meal has reached the caecum. The stylised drawing below shows a representative result from an IBS patient with serial measurements over time. The Tc99 had already reached the caecum in large quantities before the H2 PPM level has reached the threshold for an abnormal test. This demonstrates that the increased H2 production results from fermentation by colonic bacteria, not by abnormal bacteria small intestine (ie, SIBO).94
Figure 3 The lactulose hydrogen breath test (LHBT) predominantly measures small intestinal transit rather than small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS) patients. Upper schematic shows ingestion of test meal with subsequent serial measurement of both H2 gas, resulting from fermentation of the lactulose by intestinal bacteria, and Tc99 scanning in the caecum. This latter measurement detects when the test meal has reached the caecum. The stylised drawing below shows a representative result from an IBS patient with serial measurements over time. The Tc99 had already reached the caecum in large quantities before the H2 PPM level has reached the threshold for an abnormal test. This demonstrates that the increased H2 production results from fermentation by colonic bacteria, not by abnormal bacteria small intestine (ie, SIBO).94CC BY-NC · PubMed Central
Figure 4 Plot chart of currently available strategies for modifying gut microbiota aiming to demonstrate the relationship between the effectiveness and invasiveness/safety of the proposed approach. FODMAP, fermentable oligo-, di- and mono-saccharides and polyols; PPI, proton pump inhibitor.
Figure 4 Plot chart of currently available strategies for modifying gut microbiota aiming to demonstrate the relationship between the effectiveness and invasiveness/safety of the proposed approach. FODMAP, fermentable oligo-, di- and mono-saccharides and polyols; PPI, proton pump inhibitor.CC BY-NC · PubMed Central

Verification

Claims the paper makes

11 Valid · 2 Not valid · 66 Not checked · 32 Own results and interpretations

49 more claims · 1 with their cited sources checked

Create a free account to see all 111 claims and to verify the 113 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 10

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 286 references

Research works printed but not linked: 2

  1. 10.1111/j.1572-0241.2002.05475.x · DOI · Paper page
  2. 10.1111/j.1572-0241.2002.05428.x · doi:10.1111/j.1572-0241.2002.05428.x · Paper page

Cited by

See all 939

Metadata

Authors
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G.
Affiliations
  • University of Gothenburg (SE)
  • University of Bologna (IT)
  • University of Aberdeen (GB)
  • University of California, Los Angeles (US)
  • NIHR Biomedical Research Unit, Nottingham Digestive Diseases Centre, E Floor West Block, University Hospital, Nottingham, UK
  • Queen's University (CA)
  • McMaster University (CA)
  • University of Manchester (GB)
  • Wageningen University & Research (NL)
Corresponding author
Simrén, Magnus
Venue
Gut
Publisher
BMJ
Published
2012-06-22
Volume
62
Issue
1
Pages
159-176
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2135313371
Cited by
939
References
286
Citations by year
2026: 33 · 2025: 50 · 2024: 38 · 2023: 55 · 2022: 65 · 2021: 65 · 2020: 74 · 2019: 62 · 2018: 94 · 2017: 76 · 2016: 82 · 2015: 79 · 2014: 95 · 2013: 61 · 2012: 6
FWCI
74.82
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Gut (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (acceptedVersion)
  • Socio-Environmental Systems Modeling (acceptedVersion)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion, cc-by-nc)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Amgen
  • Pfizer
  • GlaxoSmithKline
  • Danone
  • Sucampo Pharmaceuticals
  • McMaster University
  • Ironwood Pharmaceuticals, Incorporated
  • Rural and Environment Science and Analytical Services Division
  • Crohn's and Colitis Foundation
  • Crohn's and Colitis Foundation of Canada
  • National Institute for Health and Care Research (NF-SI-0509-10005)
  • Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2009)
  • Astellas Pharma
  • Göteborgs Universitet
  • Marcus och Amalia Wallenbergs minnesfond
  • Nestec
  • Norgine
  • Canadian Institutes of Health Research
  • Medical Research Council
  • Sahlgrenska Akademin
  • Centrum fÖr Personcentrerad Vård
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
gut microbiota, functional gastrointestinal disorders, irritable bowel syndrome, functional dyspepsia, small intestinal bacterial overgrowth, host-microbe interactions, intestinal permeability, innate immune response, enteric nervous system, 16S rRNA gene profiling, prebiotics, probiotics, synbiotics, non-absorbable antibiotics, dietary intervention
MeSH terms
Anti-Bacterial Agents, Diagnosis, Differential, Diet Therapy, Gastrointestinal Diseases, Humans, Intestinal Mucosa, Intestines, RNA, Bacterial, RNA, Ribosomal, 16S, Probiotics, Irritable Bowel Syndrome, Metagenome, Metagenomics, Prebiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intestinal microbiota in functional bowel disorders: a Rome foundation report. https://app.cochat.ai/papers/10.1136/gutjnl-2012-302167
The paper
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013). Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. https://doi.org/10.1136/gutjnl-2012-302167

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.